Creating the blue print for the world's first
personalized, off-the-shelf affordable cancer treatment
Promising Clinical Data
Our main product has been evaluated in a finalized clinical Phase I/II-study in metastatic renal cell carcinoma with promising follow up data. A clinical phase II-trial is currently being performed in Europe. We are also finalizing a clinical Phase I/II-study in primary liver cancer. Our goal is to provide cancer patients with treatments that improve both survival and quality of life. Our research is based on platform technologies, enabling us to develop immune enhancers against a wide spectrum of cancer types.
Phase II Trials And Licensing
Our aim is to advance therapeutic cancer treatments at least through clinical phase II-trials. We intend to out-license product candidates to pharmaceutical/ biotech companies investing in the field of immunotherapies against cancer.